SARS Vaccine Development
Identifieur interne : 001248 ( Pmc/Checkpoint ); précédent : 001247; suivant : 001249SARS Vaccine Development
Auteurs : Shibo Jiang [États-Unis] ; Yuxian He [États-Unis] ; Shuwen Liu [États-Unis]Source :
- Emerging Infectious Diseases [ 1080-6040 ] ; 2005.
Abstract
Developing effective and safe vaccines is urgently needed to prevent infection by severe acute respiratory syndrome (SARS)–associated coronavirus (SARS-CoV). The inactivated SARS-CoV vaccine may be the first one available for clinical use because it is easy to generate; however, safety is the main concern. The spike (S) protein of SARS-CoV is the major inducer of neutralizing antibodies, and the receptor-binding domain (RBD) in the S1 subunit of S protein contains multiple conformational neutralizing epitopes. This suggests that recombinant proteins containing RBD and vectors encoding the RBD sequence can be used to develop safe and effective SARS vaccines.
Url:
DOI: 10.3201/eid1107.050219
PubMed: 16022774
PubMed Central: 3371787
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
PMC:3371787Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">SARS Vaccine Development</title><author><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name><affiliation wicri:level="2"><nlm:aff id="aff1">New York Blood Center, New York, New York, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>New York Blood Center, New York, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="He, Yuxian" sort="He, Yuxian" uniqKey="He Y" first="Yuxian" last="He">Yuxian He</name><affiliation wicri:level="2"><nlm:aff id="aff1">New York Blood Center, New York, New York, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>New York Blood Center, New York, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Liu, Shuwen" sort="Liu, Shuwen" uniqKey="Liu S" first="Shuwen" last="Liu">Shuwen Liu</name><affiliation wicri:level="2"><nlm:aff id="aff1">New York Blood Center, New York, New York, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>New York Blood Center, New York, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">16022774</idno><idno type="pmc">3371787</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3371787</idno><idno type="RBID">PMC:3371787</idno><idno type="doi">10.3201/eid1107.050219</idno><date when="2005">2005</date><idno type="wicri:Area/Pmc/Corpus">001756</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001756</idno><idno type="wicri:Area/Pmc/Curation">001756</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">001756</idno><idno type="wicri:Area/Pmc/Checkpoint">001248</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">001248</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">SARS Vaccine Development</title><author><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name><affiliation wicri:level="2"><nlm:aff id="aff1">New York Blood Center, New York, New York, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>New York Blood Center, New York, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="He, Yuxian" sort="He, Yuxian" uniqKey="He Y" first="Yuxian" last="He">Yuxian He</name><affiliation wicri:level="2"><nlm:aff id="aff1">New York Blood Center, New York, New York, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>New York Blood Center, New York, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Liu, Shuwen" sort="Liu, Shuwen" uniqKey="Liu S" first="Shuwen" last="Liu">Shuwen Liu</name><affiliation wicri:level="2"><nlm:aff id="aff1">New York Blood Center, New York, New York, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>New York Blood Center, New York, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author></analytic><series><title level="j">Emerging Infectious Diseases</title><idno type="ISSN">1080-6040</idno><idno type="eISSN">1080-6059</idno><imprint><date when="2005">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Developing effective and safe vaccines is urgently needed to prevent infection by severe acute respiratory syndrome (SARS)–associated coronavirus (SARS-CoV). The inactivated SARS-CoV vaccine may be the first one available for clinical use because it is easy to generate; however, safety is the main concern. The spike (S) protein of SARS-CoV is the major inducer of neutralizing antibodies, and the receptor-binding domain (RBD) in the S1 subunit of S protein contains multiple conformational neutralizing epitopes. This suggests that recombinant proteins containing RBD and vectors encoding the RBD sequence can be used to develop safe and effective SARS vaccines.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct></listBibl></div1></back></TEI><pmc article-type="review-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Emerg Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Emerging Infect. Dis</journal-id><journal-id journal-id-type="publisher-id">EID</journal-id><journal-title-group><journal-title>Emerging Infectious Diseases</journal-title></journal-title-group><issn pub-type="ppub">1080-6040</issn><issn pub-type="epub">1080-6059</issn><publisher><publisher-name>Centers for Disease Control and Prevention</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">16022774</article-id><article-id pub-id-type="pmc">3371787</article-id><article-id pub-id-type="publisher-id">05-0219</article-id><article-id pub-id-type="doi">10.3201/eid1107.050219</article-id><article-categories><subj-group subj-group-type="heading"><subject>Synopsis</subject></subj-group><subj-group subj-group-type="article-type"><subject>Synopsis</subject></subj-group></article-categories><title-group><article-title>SARS Vaccine Development</article-title><alt-title alt-title-type="running-head">SARS Vaccine Development</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Jiang</surname><given-names>Shibo</given-names></name><xref ref-type="aff" rid="aff1">*</xref></contrib><contrib contrib-type="author"><name><surname>He</surname><given-names>Yuxian</given-names></name><xref ref-type="aff" rid="aff1">*</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Shuwen</given-names></name><xref ref-type="aff" rid="aff1">*</xref></contrib><aff id="aff1"><label>*</label>New York Blood Center, New York, New York, USA</aff></contrib-group><author-notes><corresp id="cor1">Address for correspondence: Shibo Jiang, Lindsley F. Kimball Research Institute, New York Blood Center, 310 East 67th St, New York, NY 10021, USA; fax: 212-570-3099; email: <email xlink:href="SJiang@NYBloodcenter.org">SJiang@NYBloodcenter.org</email></corresp></author-notes><pub-date pub-type="ppub"><month>7</month><year>2005</year></pub-date><volume>11</volume><issue>7</issue><fpage>1016</fpage><lpage>1020</lpage><abstract><p>Developing effective and safe vaccines is urgently needed to prevent infection by severe acute respiratory syndrome (SARS)–associated coronavirus (SARS-CoV). The inactivated SARS-CoV vaccine may be the first one available for clinical use because it is easy to generate; however, safety is the main concern. The spike (S) protein of SARS-CoV is the major inducer of neutralizing antibodies, and the receptor-binding domain (RBD) in the S1 subunit of S protein contains multiple conformational neutralizing epitopes. This suggests that recombinant proteins containing RBD and vectors encoding the RBD sequence can be used to develop safe and effective SARS vaccines.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords: </title><kwd>SARS</kwd><kwd>SARS-CoV</kwd><kwd>spike protein</kwd><kwd>receptor-binding domain</kwd><kwd>Neutralizing epitone</kwd><kwd>vaccine</kwd></kwd-group></article-meta></front></pmc><affiliations><list><country><li>États-Unis</li></country><region><li>État de New York</li></region></list><tree><country name="États-Unis"><region name="État de New York"><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name></region><name sortKey="He, Yuxian" sort="He, Yuxian" uniqKey="He Y" first="Yuxian" last="He">Yuxian He</name><name sortKey="Liu, Shuwen" sort="Liu, Shuwen" uniqKey="Liu S" first="Shuwen" last="Liu">Shuwen Liu</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Pmc/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001248 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd -nk 001248 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Pmc
|étape= Checkpoint
|type= RBID
|clé= PMC:3371787
|texte= SARS Vaccine Development
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/RBID.i -Sk "pubmed:16022774" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |